CD Formulation offers specialized services in analyzing the molecular weight of nucleic acid drugs, like siRNA, to help researchers better comprehend these essential molecules. These drugs consist of long nucleotide chains, possessing molecular weights between a few to several dozen kDa. Accurate molecular weight analysis provides vital data that supports the enhancement of nucleic acid drug performance.
Molecular weight analysis is crucial for nucleic acid drugs as it dictates their stability and pharmacokinetic profile within the body. Accurate measurement aids in understanding these drugs' mechanisms and supplies vital data for their development and refinement. Discrepancies in molecular weight can impact efficacy and activity, making thorough analysis essential. This not only helps ensure product quality but also supports informed scientific research and development decisions.
Nucleic Acid Drugs | Length | Molecular Weight |
---|---|---|
ASOs | 8-50 bases | 5-10 kDa |
siRNA | 21-23 bases | 13-15 kDa |
miRNA | 20-25 bases | 18-23 kDa |
mRNA | Range from tens to thousands of base pairs | 20-40 kDa |
Aptamers | 50 to 120 bases | Based on their sequence length |
Items | Descriptions |
---|---|
Pretreatment of Nucleic Acid Drugs | Preparing these drugs for analysis is tricky since nucleic acids degrade easily and bind with biomolecules. Techniques like liquid-liquid and solid-phase extraction are used to boost nucleic acid recovery and reduce protein and impurity interference. |
Molecular Weight Analysis | Typically, HPLC with mass spectrometry (LC-MS/MS) is used to precisely measure nucleic acid drug molecular weights and oligomer distributions. This approach also enables the study of single and double-stranded structures. |
Mass Spectrometry Optimization | Mass spectrometry signals can suffer due to ion distribution issues and cation interference. Addressing this may involve tweaking the ESI source, adding volatile cations, and optimizing chromatographic conditions. |
Fig.1 Flow chart of nucleic acid molecular weight analysis. (CD Formulation)
Remove proteins and contaminants from nucleic acid drug samples to ensure they don't affect analytical results.
Perform initial quality checks on samples to confirm they meet analytical standards, focusing on concentration and purity.
Choose the best analytical technique, such as mass spectrometry or gel electrophoresis, based on the nucleic acid drug's characteristics.
Gather data on nucleic acid drugs' molecular weight using chosen techniques, and analyze results with specialized software for accuracy.
Validate analysis results, perform reproducibility tests for reliability, and compile a detailed report with methodology, data, and conclusions.
Platforms | Descriptions |
---|---|
HPLC Platform | HPLC is utilized for determining nucleic acid drug molecular weights through effective separation and identification via suitable columns, mobile phases, and gradients. |
MS Platform | Mass spectrometry, often paired with liquid chromatography, provides precise molecular weight data, enhancing sensitivity and accuracy for nucleic acid drug detection using methods like ESI. |
Gel Electrophoresis Platform | Gel electrophoresis (agarose or polyacrylamide) separates nucleic acid fragments by size, offering rough molecular weight estimates, though less precise than mass spectrometry. |
To ensure optimal performance of nucleic acid drugs during development and application, CD Formulation provides detailed molecular weight analysis services. Utilizing advanced technology and instruments, we accurately assess and characterize the molecular weight properties of nucleic acid drugs, offering researchers and developers reliable data support to aid in in-depth research and product optimization. If you have related needs or inquiries, please feel free to contact us.